Nutley, NJ - An injectable form of ibandronate (Boniva, Roche/GlaxoSmithKline) that can be given once every three months has been approved by the US Food and Drug Administration (FDA) for treatment of ...

Ibandronate (as sodium) 3mg/3mL; soln for IV inj. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone ...

WASHINGTON, June 7 (Reuters) - Patients who want an injectable form of Roche Holding AG's bone-strengthening drug Boniva may not be able to get it in the next few weeks because the company did not ...

A new treatment for osteoporosis that can be given just once every three months has been approved by the US Food and Drug Administration. A new treatment for osteoporosis that can be given just once ...

March 31, 2005 — The U.S. Food and Drug Administration (FDA) has approved a once-monthly formulation of ibandronate sodium for the treatment and prevention of postmenopausal osteoporosis; entecavir ...

While drug shortages often are tied to manufacturing interruptions, Roche's ($RHHBY) injectable form of its osteoporosis drug Boniva will be in limited supply for ...

Ibandronate is the only bisphosphonate approved for once-monthly oral dosing, because of its particularly long half-life. Other intravenous bisphosphonate formulations have to be infused slowly to ...

Many companies have been caught off-guard by the extent to which generic competition has eaten away at their sales. Genentech says it managed to be caught off-guard by a lack of it, leading to a ...

Ibandronate (as sodium) 3mg/3mL; soln for IV inj. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone ...

WASHINGTON (Reuters) – Patients who want an injectable form of Roche Holding AG’s bone-strengthening drug Boniva may not be able to get it in the next few weeks because the company did not accurately ...